Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBINE 4: weekly IcoSema versus daily insulin glargine in insulin-naive adults with type 2 diabetes
2022-502484-38-00Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing IcoSema once weekly with Insulin glargine once daily (2 arms). Primary endpoint: Change in HbA1c. Started Oct 2023; status: completed.
02
Drugs
icosemainsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2022-502484-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502484-38-00.